PCT/GB97/00074

The Patent Office

The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 28 JAN 1997

Patents Form 1/77

.ct 1977
(h. .)

The Patent Office

15JAN96 E167095-10 000335
P01/7700 25.00

£25.00

10 JAN 1996
LONDON

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference JDM/DCS/P93928GB

2. Patent application number *(The Patent Office will fill in this part)* **9600470.0** 10 JAN 1996

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

THE UNIVERSITY OF LIVERPOOL
SENATE HOUSE
ABERCROMBY SQUARE
P.O. BOX 147
LIVERPOOL, L69 3BX
ENGLAND

Patents ADP number *(if you know it)*

If the applicant is a corporate body, give the country/state of its incorporation

ENGLAND
8911840004

4. Title of the invention

METASTASIS INDUCING DNA'S

5. Name of your agent *(if you have one)*

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

W.P. THOMPSON & CO.,
COOPERS BUILDING
CHURCH STREET
LIVERPOOL L1 3AB

Patents ADP number *(if you know it)* 0000158001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number	Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

YES

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	
Description	17
Claim(s)	
Abstract	
Drawing(s)	6

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature [signature] Date 10/1/96

12. Name and daytime telephone number of person to contact in the United Kingdom D.C.SCHILLER 0151 709 3961

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*

b) *Write your answers in capital letters using black ink or you may type them.*

c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*

d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*

e) *Once you have filled in the form you must remember to sign and date it.*

f) *For details of the fee and ways to pay please contact the Patent Office.*

DESCRIPTION

METASTASIS INDUCING DNA'S

The present invention relates to metastasis inducing DNA's, a method of identifying such DNA's, and their use in diagnosis and therapy.

Most cancers are thought to be due to alterations in specific genes caused either by mutation making their gene-product in some way more effective or by overexpression of a normal gene giving an enhanced effect. These oncogenes have largely been identified by introducing gene-length fragments of DNA from human cancers into a mouse fibroblast cell line, in culture, and selecting those cell lines that grow in an uncontrolled manner in liquid or semi-solid medium. The oncogenes themselves have been isolated by cloning the human DNA fragments away from the mouse DNA by standard recombinatorial techniques. Alternatively mutations can arise in genes that suppress their own activity such as, for example, p53 or Rb or which suppress the levels of their products such as, for example NM-23. These are referred to as tumour suppressor oncogenes. In the commonly-occurring cancers, it is believed that between 5 and 7 such changes in oncogenes or tumour suppressor oncogenes are required to produce a full-blown cancer.

The major forms of cancer, including breast

cancer, lung cancer and colonic cancer cannot be cured effectively because, although the current therapies may be effective against the primary tumours, they are largely ineffective against the disseminating or metastasizing cells, which ultimately kill the patient. Despite the enormous effort in cancer research very little is known at the molecular level about the most important life-threatening process, that of metastasis. Most of the oncogenes and suppressor oncogenes that have been discovered have been found from their ability to promote uncontrolled growth of the mouse fibroblast cell line. The major problem in this field is that determining cell growth does not give a measure of the process of metastasis. In fact, although uncontrolled growth is an important aspect of the initial events in the development of a cancer, the rate of growth of distant metastases can be remarkably slow. Hence the process of metastasis is largely independent of processes involving cell-growth, except in its final phases. Therefore, it is unlikely that oncogenes and tumour suppressor oncogenes will have much involvement in the process of metastasis and be useful diagnostic or therapeutic targets for control and elimination of metastatic disease.

It is one object of the present invention to

identify DNA comprising, consisting of or containing sequences involved in metastasis, hereinafter referred to as metastasis inducing DNA's or Met-DNA's for short.

According to a first aspect of the present invention there is provided a method of screening and recovering Met-DNA comprising the steps of:

1. transferring fragments of human DNA from malignant, metastatic cancer cells into a cell line that produces only benign, nonmetastasizing tumours when injected into syngeneic animals;

2. injecting the transformed cells into a syngeneic animal;

3. selecting those animals in which metastasizing tumours have been identified; and

4. recovering the Met-DNA therefrom.

Preferably the DNA fragments transferred in step 1 are fragments of from 0.5 to 50k base-pairs.

Preferably the cell line that produces only benign non-metastasizing tumours when injected into syngeneic animals is a rat mammary epithelial cell line, such as, for example Rama 37.

Preferably the fragments of human DNA from malignant, metastatic cancer cells are tagged to assist in their removal or insertion from or into a host or vector, such as, for example, the

oligonucleotide tag illustrated in Fig. 1. This tagging procedure overcomes the problem of identifying the inserted human DNA sequences in the rat genome of the transfected rat cells. Human-specific repetitive DNA (Alu) sequences are spaced sufficiently in the human genome that in many human DNA fragments of this size they will be absent.

In one embodiment, fragments of human DNA from malignant, metastatic breast cancer cells are introduced into a rat mammary epithelial cell line Rama 37 which produces only benign, nonmetastasizing tumours when injected into syngeneic rats.

By way of example only, the transfer of restriction-enzyme HindIII-fragmented DNA from malignant metastatic rat and human breast cancer cell lines into a benign Rama 37 cell line produced a small proportion (1-3%) of transformants which, when reintroduced into the syngeneic rats, caused these cells to metastasise, principally to the local lymph nodes and lungs. In contrast, fragmented DNA from nonmetastatic cells and the standard oncogenes (Ha-ras, Middle T Antigen gene, and Large T Antigen gene) produced no metastasizing transformants. The latter result confirms the non involvement of such oncogenes in the metastatic process per se. However, the fact that metastasis can be transferred in a genetically

dominant manner suggests that other dominantly-acting DNA fragments are largely responsible for this process. The full results of the above experiments are shown in table 1, which shows the incidence of tumours and metastases for Rama 37 transfected cell lines.

The column headed cells injected give the cell type in short hand, and full details are given below:

Rama 37 are Rat mammary 37 benign cells; R37-Ca2-LT1 is a cell line from a lung metastasis of Rama 37 cells transfected with fragmented DNA from the metastatic breast carcinoma cell line Ca2-83 (Cancer Res 54 2785-2795, 1994); B-T1 is a cell line from a primary tumour of Rama 37 cells transfected with fragmented DNA from the benign breast cell line HMT-3522 (Cancer Res. 54 2785-2795, 1994); R37-Ca2-HT is a cell line of Rama 37 cells transfected with tagged DNA fragments from metastatic transformant R37-Ca2-LT1; R37-Ca2-H is a cell line of Rama 37 cells transfected with untagged DNA fragments from metastatic transformant R37-Ca2-LT1; R37-B-HT is a cell line of Rama 37 cells transfected with tagged DNA fragments from the benign transformant B-T1 as a control; R37-F1 is a cell line of Rama 37 transfected with PCR fragment F1 from a cell line of a lung metastasis of R37-Ca2-HT; and R37-F2 is a cell line of Rama 37

transfected with PCR fragment F2 from the same cell line of a lung metastasis of R37-Ca2-HT.

The b annotation in the column headed metastases identifies the transfecting DNA's giving rise to significantly more metastasis than Rama 37 cells ($P<0.05$, Fisher exact test). The animals were autopsied after 3 months.

To aid the rescue of metastasis-inducing human DNA sequences from the rat transformant cell lines, all the HindIII-fragmented DNA's from one such metastatic transformant, R37-Ca2-LT1 (Table 1) were tagged at both ends with double-stranded synthetic oligonucleotides that provide restriction enzyme and unique PCR primer sites. These are shown in Fig. 1 The tagged DNA fragments include 4 restriction sites: SfiI and NotI, a defective HindIII site at the 3' end for linking to the HindIII sites at the ends of the human DNA fragments, thereby destroying it, and an internal HindIII site located near to the 5' end, which when cut after ligation generated new fragments with HindIII ends. The fragments were transfected into the parental Rama 37 cells, and after transfer of the cells to the mammary glands of syngeneic rats, metastatic cell lines were isolated from the resultant rat lung metastases. The tagged, fragmented DNA incorporated into the metastatic transfected Rama 37

cell lines was directly amplified between the tags by PCR and yielded bands at about 1300 to 1500 bp that were responsible for the metastasizing ability of the transfected cells. These results are shown in Fig. 2 which shows the DNA fragments produced by PCR of metastatic transformants. Two new cell lines, established from the culture of lung metastases of R37-Ca2-HT (tagged, metastatic DNA transformant) and R37-Ca2-H (untagged, metastatic DNA transformant) (see Table 1) in rats were termed HTLu and HLu, respectively. They were run against the tagged benign transformant cell line R37-B-HT and the tagged metastatic transformant R37-Ca2HT. Cellular DNA was amplified by PCR using a short oligonucleotide primer of 22 bp from positions 3-24 of the tag sequence as shown in Fig. 1. Compared with the control DNA's from HLu and B-HT cells, two extra bands, F1 and F2, of about 1300 bp and 1500 bp respectively, were specifically amplified from genomic DNA of the Ca2-HT and HTLu cells when PCRed DNA samples were run on 0.8% agarose gels containing ethidium bromide and photographed in U.V. light. The fluroescent bands of DNA are shown in negative imaging for clarity. Cloning of these pooled DNA's yielded six independent fragments and the results are illustrated in Fig. 3. Fig. 3 shows pBluescript clones of metastatic DNA

fragments F1 plus F2. The two broad PCR DNA fragments F1 and F2 were excised from the gel in Fig. 2, combined, and cloned directly using the AT procedure into a suitably modified pBluescript vector and the clones of recombinant vectors (C10,C9 etc) were cut with HindIII to excise the cloned fragments. These cut recombinant vectors were analysed on a 0.8% agarose gel containing ethidium bromide and photographed in U.V. light. The sequences of clone C10 and C9-DNA's were identical; vec = vector DNA and ins = insert DNA corresponding to the cloned DNA of about 1000 bp. Transfection of these cloned DNA fragments singly into the parental benign cell line confirmed that all fragments (C2,C5,C6,C9,C12 and C20-DNA's) produce metastases. These are shown in Table 2 which tabulates the incidence of tumours and metastases for Rama 37 cells transfected with cloned Met-DNA's. The superscript a & b indicate:

[a]Nomenculture: pSV2neo, benign Rama 37 cells transfected with the selection vector for the cloned DNA fragments alone; C2-DNA, benign Rama 37 cells transfected with the vector and the insert from clone 2 of the pBluescript library of the F1 and F2 pooled DNA's, and similarly C5 to C20 -DNA.

[b] indicates significantly more metastases than vector transfected Rama 37 alone ($P<0.05$, Fisher exact

test). Animals were autopsied after 3 months.

Thus Koch's postulate has been satisfied for all metastasis-inducing-DNA's (Met-DNA's) in this system.

Southern hybridisations and PCR amplifications have established that the Met-DNA's are specifically present in their respective transformants.

Fig. 4 shows detection of C9-DNA in transformant cell lines. Cellular DNA was isolated from (A) a cell line from a lung metastasis produced by injection of C9-DNA transfected Rama 37 cells in rats; (B) C9-DNA transfected Rama 37 cells (see Fig. 3 and Table 2); (C) benign Rama 37 cells; (D) benign BT-1 cells (see Table 1). These DNA's were digested with HindIII and the digested DNA was analysed on 0.8% agarose gels either by (A) Southern blotting to a probe of [^{32}P] radioactively labelled C9-DNA, and the radioactivity visualised on X-ray film or (B) by PCR using the 17 oligonucleotide fragment from either end of the C9-DNA as primers and run with a standard molecular weight marker ladder. The newly synthesised DNA in B is visualised by fluorescence of the ethidium bromide in the gel in U.V. light. Surprisingly, the sequences of these Met-DNA's illustrated in Figs. 5 to 10, although human in origin, do not correspond to known genes and most do not include any obvious open reading frames. Furthermore none of these Met-DNA's

are expressed as mRNAs in their transformants and hence are not dominantly-acting oncogenes. They therefore contain entirely novel short stretches of regulatory DNA capable of inducing metastasis.

According to a second aspect of the present invention there are provided DNA comprising, consisting of or containing the metastasis inducing DNA from the sequence:

C2

CTTCCTTGGT GCTCTATGTC TTGCCTCTCC CCTTCTCCAG TCCCATTAAG CCATAACCAT
CTTGACAGAC TCTGGGACAG TCCCCTCTGC TCTCCTGTTG GCGCCTGAGT CCCTTTTTGC
CTGAGGACCC TTCACGTAGC CTCCCATCTG GATGACCTAG TAGAAGACGT GGGAAGTTGT
CACACTCAGG TAACTGAGCA GAGCTCAGAG ATTTAAAGTG AGTCTGGGGA GCCTCGAGGA
TTGATCTGCT GCCTTAAAAA GCCAATTGGA TGACTAACCC AGACTATTGT CACTTTAGGT
GGGAAGTCAC TAGCATATCT GATGGGTCAC ATCTGAGAAA GGTTTCTAGC AGTGGTGGCC
TTGTGTGAGC AGCATGGCGT GTATCATGGT GTGCAGCATA CTCAGGCTGC TTGCAACACT
CGAGGCTCTT CTTCAGTATT AGGGGAACCA CTGGTGTTSG AACATGGTCC AAGAATACAG
TCATGTGAGG AGAATCCCAA TGCGTCAGGA GAAAACGAGA GTCTGTGACC TCCATTCTTC
AAGATACAGA ATTATTCTTG GACTGTGTTT TCATGCTCCT TGTGGATGGG AGTGAGTTTA
CTTCAGGTTA ATCAGCATTG CTTACTGTTG GTATTCAAGT AAATGCTTAA ATTATCCTGG
ATATACCTCT GTGGGAAGCA GGTTTTTGAT ACATGCAGCT TGTCCTTGTG ATTGATACTG
CTTGAACTCA AGAGAACTTT GCTCATGTGA TCTTTCTTAA CCGATGGAGT AGAAACTGTC
TGATGCTCTC AATAAAGTTG GCTCTTGCAC GAGACGTTAG TCTGTCCTGT TTATCTGCTC
CATTCTTCCG CTCCCACGGC CTCTACAGCA CTAAACCCAC CACCGATAGA CTCAGTCTTT
CACTGACAAA CATCACCAGA GGCTCTTAAC TGAGATTATA AACTGTTACT AGATGATGGG
TGGAATCGCT CCCCAGAAAC ATAAACATTT ACTTGGAGAA CTCAAGACCC CTTTGTAGAC
ATAACTCCCA TGGT

According to a third aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C5

ATTGCTGTGA GCCTATTAGC GACATTTGGT GACGCCCCTT TTAAGGGGGT AGATACAAAG
AATGGGTTGA AATTCTGTGC CACAAACGCT CTCCATGTTT TCACAATTAC ACTTGCAACC
TGTGGTCAGC AGCCAGAATT TAGGGATGTG ATGGGACAGG GTCGGGGAAA GAAGGAGAAG
GGTAAAGGAA AGACAGCACG TTAAAGTCCA AACAGCTCCA GGAGACTATC TGTAGAAATA
ACATCAGACC ATGAGGAGAA TTGATATCAT TGTTTTTCAA TGGGTATCGC CAAGGGAACT
TTCCATCTGA TTAAAAATAA TTACTGCTGG CACTAAATCC AATTGGAAAT GCCCCACACA
ATTTATCTTC CACTTCATGC TGCTACCATA TGCCTGACGT GGCGGAGCAG AAGCATTCCC
TCCCGTTCTG ATAAATAGTA CTTTGTAAAT ATTTGGAGAC GGGAGCTCTG GTGACAGGGA
ACACGTACAA ACCGGCCTGT TTATCATGTT CCCGATAGAG GCCCTCTTTG ACGTACAGGA
CCCCAAAACA GTCAGGATGC TGTGAATTTC CTTCCATGAA GCCTTGTTCA CAATTAGCAA
CCATTGGAGG AAGCAGGCTG CACTGTCTAC CACAAGTGGC ACTTTCCAAA GAGCACACAT
ATATTGGAGC AAGACATTTT GCTGGCTGAC TGGTGCTGTG TAAGCTGATA AACTGCTATA
TTTATTAAAC TGGCTTTTCT TTGAACACCC CACTCAAGGA AAAAAAAACA CACTTAGGGT
GACATTATTT GGAGATGAAG TCTTTATAGA GATGCTTAAG TTTAAACGAG ACTTTTAAAG
CCGGCTCTAT TCCATTTAAT GAATGGTGTC CCTACAAAGG AAGAAACTGG GACAGAGGTA
TGTACACTTG TGTGTGTGTG AGAGACAACG TGAGGAGCTG AAGAGGAGCA CGTACAAGTC
AGAGAAAGGC TGACCCTTAT TCACACTGAG CAAACCAGTC ATGTGTGGGT CGATAGATGA
GAGTATCCCC CAAGACTCAC ACATTCGAAC GCTTGGTC

According to a fourth aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C6

AGGACCAGAG TTCACATCCC ATCAAATGGC CCAGAAGGTT TTAATGCTGT CTTTTGGCCC
AGGGGCGAAC TGCACACACA TGTGCACATA CACTTACAGA GACACACATT CAGCAGCATA
AGAACACAAT CACAAATAAA AAAAATCTTG AAAAATTTTA AGCTAAAATT GTTAAGAAAT
AACATATATA CAATTTTTCT TTATTTTTTT AAAGATTTAT TTATTTAATG TATATGAGTA
CACTGCCTCT CCCTCCAGAC ATAGCAGTAC AGGGCATCGG ATCCCATTAC AGATGGTTGT
GAGCCACCAT GTGGTTTCAC AGATGGTTGT GAGCCACCAT GTGGTTTCAG GAATTGAACT
CAGGACCTTT GGAAGAGCAG TCAGTGCTCT TAACCTCTAA GCCATCTCTC CTGACCCTTA
TATACAATTT TAATGCTACG TACACACAAC TTCTCTTTCC TTTAATGGTT GAGATTTTTG
TCTGGAGAAG TAAGAATAAA GGAGGGAAAG AACATTGCTT TCACATTGCA CCAGTGGGAA
CAGCGTGTTT AAAGTAGGAA TGCCATGAAA TGACTGGCCT GCCTTCTCAT TACTGTTCCT
CCCACTCCTC CTTTTAACTG GAGCTCCTTT ATCTAATTTA TTAGTTTGAC GATACCCAGG
GTTTTCTTCT GTTTTGATCT TTTTAAGACA GAGACTCACC ATATAGCCCT GGCTGGCCTG
AAGCTCACTA TGTAGACCAG TCTGGCCTTG AACTCAAAGG AGATCTATCT GCTTCCTAGT
GCTGGGATTA AAGGCTTGTG CTACCAAGTC TGGTCTGAGG CTTTGGAGCA GCCTCGGTTT
TGGCCTTCTT TAAGGATCTC TAAGCTAGCA GTAAGTAGCC TAGCCATGCT GTTGTAGGAA
GTTGTTCGTT CATCCTGGCT CCAGCACAAA GGCAGTCACT AAACGTCGGC CTCATTTCAT
CAGAGCTGAA TGCAAATTCC TTGTGCTCTT CCTGTGTCCT CCTGGAAC

According to a fifth aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C9

AGTTGGGGAC ACAGCTTGCT TGATTAAGAT GTTTCTTGGG AAAAGGAGTT AAGCCTAATG
ATTTCCAATG GAAAGGACTG CTAATTGGGG AGGCAATGTT GCTTAATTGG GACACCTGCG
GGTAATTAAA AGCTCTCTCC CAGTGGCCTT TCCTGTTTTT GGCTCTGGGA GGCGAAGGCA
TTGAGAGGGA TGCAGGCATT CTAAGGGCTG GTTCTTGGTT TCTCCCTTCC CCTCTGTCCA
AACTCAGTGA GGTATCCCTG TCTGTGCTGT CCTTAGAGTG CCGTCCTGAG GCCTTGGTGA
GTTAAGGTCT CTGGATCTGA GCTGCCTCAG GGAAACGCAT GAGCTCATTG GAAAGGGGAG
AACCAGGCAA AGGTGTTGGC TGTGACCTCA GAATTCTGAG GGGCAAAGGT TCAAGGCTAA
CTCTCATTAT AGAGCAAGTT TGAGACTGGC CTGGGAACAA AAATATAAAG TGAGTGAGGT
CATATGACAG CACCTGAGGA GTCCTGTCCC TAGAGATCAT AAGGACCTGG CTGCTGGGGA
CTTGTTGCAG ATGGCACTTT GTGTCGAGAG AGGGGACCTG CCCCAGCATG GGAGGCCCTG
GAAGATCCTC TGGATTAACT GTGAACACTG ATTGCTGCTT TATACCTGGA GTTGTGCTGT
TATCTGGTAC ACATCTGCTG GGTGAATGAG TTCATGGGCT TTATTTCAGT GAGGTATTTA
CCTGAGGAGA AAGAAGGACT GGTGCCACAA AGCACAGCTT TTAAATCTGT GGGTTGTGAC
CCATTATGGA CTATCATAAC TGAGTGCAGG TATCAAGAAT ACTTTAGCAG GTGGTAAAAA
GATTTTTGAA TGCGCAACGA CCAAAACTGA ACTCAAAAAT CAAGCATGGC ATGGATCCTG
GGTGCTCCTG GAAGCACTTG CCTTTACTGC ATTGTGCGAC TTGACGGTAG CCTTGGTTCT
GAATGCACAA CACGTGGGCT TTGGGCTGCA CAGGCCACCA CGCCGTGCCT GAAACACCTC
AGCTCAGGTT TGTGGCTATG TCCTATGACT TGGACTTACT TTTATTGCAC ATATAAATAT
TTTCCTGC

According to a sixth aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C12

GAGGGGGTGG TGGCACAGTT ATGTTTTTGT AGGAAGGGTT CCATGAACCT CAGCAGAGCT
CGGGTTAGAA ATTTAAAAGC CCTGAGGGGA ATTTTTTTTT TAAATCGCTA TGAATCTGAC
ATGAGAAAAA CAGATCAGAA ACGTTCTTGT GCTTCAGAAA AGGACAAGTG TGTGAGCTAA
CAGACTGCAC ACTGGTGTTC GAGGCACATC TGGATCACAG GAGCGTCAGA TAATGTCCCC
AAAGGTAAAT GCATTTGCTT GCACAGTACC GAGTGTGGTG GGGGGTGCCT ACAGCCCAGC
GGTTCTCAAC CTTCCTGATG CTTCGACCCT TTAATACAGT GCCTCATGCT CTGGTGACCT
CCCCAACCTT AAAATTATTT TTGTTGCTGT TCATAACTGT GATTTTGATA CTGTTATGAA
TTGTAATATA AATAATTTTG AAGAAAGAGG TTTGCCAAGG GTTTGAGAAC TGCTGTTCTA
GCCCCACGTG GATGGTTTTT CGTCATTTGG GGTTTTTATG AGGCAGAGTC TTATGTAGCC
CAGGCTAGCA GCCTAGAATG TGCTACTTAG CTGAGGAATA ACCTTGGAAC TTCTGAGGAC
TGGAGAGACT GGCTTAGTCC TCAAGAAACT GGAAATAGCT GGAGTTTGGC TACTTGTGGG
TTCCTTTTTC TTCAAACCTT TTCTACTCTT TTTCCACCCT GTCGGCCCCC TAACACTAAA
TAAGAAAGAG AAAGGGGAGC ATAGAGGGGA AAAGAAACCC CTGAATAACG TCAGTAGTTG
GCAAAGGGGG GTGACATATG TTGTCATTAG ACCACATCCT GGTGATTAAG GGGAGTCAAG
TTCCTTGGGG CAAGTTTGAT CTTTCGTGTA ACGATATCTA ATTTCTTCTC CCTGTTGCTT
CGTCTTTGTG AACAACGACT TGATAACCCA CAATGGACCA TCAACCAACC AACCAACCAT

According to a seventh aspect of the present invention there are provided DNA comprising, consisting of or containing a metastasis inducing DNA from the sequence:

C20

TTGTCTCTGG TGTTACTTGT TTTCCCATTT CTGACAGTGG TTTGACCTT CTATACGCCT
GTGTGTCAGG AGTGCTGTAG ACCTATTTTC CTGTTTTCTT TCAGCCAGTT ACAGGAACAG
AGTGTTCTAC TGTCAGATGT GTAGCTGTTC CTGTCCACTG ACTTTCAAGC TGTCTCTGTG
TGCAGGAACC AGAAGGGCCT GTCCCTACTT CTACTGGGCC CCTACGCACA GGGGGCCTAG
ATGGTGCTAG GTGTTTTCCT CTAGAGCCTG AAATGTGGGC AGAGAGTAGT CTCCTCTGGT
TTCCTAGGTA TGTCTTCCCC TCTGAAGGTC TAGCTCTCCC TTCCATGGGA TATGGGTGCA
GGGAGCTGTT TGACCAGGTC CTCTCAAATC CGGGTGCAGT CTGGACCGCA GGCTCCTGTA
GCTTGCCTGC TGCAATCTTC CCGCACCCAG AGGCACCCAA GTTTCCTCTT GGGCCAAGGA
TGTGGGCAAA GGTGGGCAGA AGTGGCAATC TCTCCTGCCC TAGCGTCTCA GGATTGCCCT
CACTTCTGGG CAATCCGCTC TCTCTTCCAC AGGGTTTGGG AGCAGGGAGC TGTGGGCCGG
TATCAGGCAA AGGTTTGAGG CAACCAGTTA GAAACTGGAA GTGTCAGGTC CCAGAGGAAT
TTTGCCTTTG TGTGTCCTGA GTCCACCAGG CAGGTCACTT GGAGCAGAAA AATTGGTTTT
CCCCTCGGTC TCAGGCCTGA AGTTGCACCT CAGGGTTGGC TTTCAGCTGT ACCTGTGGAA
AGTATGGTTT TAAAAATCTA AGATAGCTAT CATGCAGCAA GGCTTGTGTA AAATGTCTAT
TTGGTTCCTT TATGACTTAC TTTTGCTGTA CTGAGGATCA AACCTAGGGT CTCAAGCAGT
CATCACAATT CTCTGTCACT GATCCAGCTC CATTTCTATT TTCTTTTGTC CCGCGCGATC
TCTCGCCAGC AAGAAAACAC GCTAGGGACA TACGAATCCT TGCTGCAGCC AAAACTTTTA
TTGAATCTTA AGGAGAAGCC CGCGCACCGG ACTGGCGCGG TTTATATACA CCCTAGCACA
GTGCATCCAC A

According to an eigth aspect of the present invention there is provided a method of detecting metastasis inducing or inhibiting genes by screening for differences between the messenger RNA expressed between Met-DNA - transfected and nontransfected cells.

In one embodiment Met-DNA's, are introduced into a benign rat mammary epithelial cell line Rama 37.

By way of example and to help identify the regulatory function that short stretches of human malignant DNA (precursor to Met-DNA's) may exert on the transfected Rama 37 cells, the mRNA expression of the metastatic transformant rat mammary cell line R37-Ca2-LT1 was compared with its benign parental cell line Rama 37 using subtractive hybridisation techniques. Of the four subtracted clones three corresponded to known rat genes for proteins including osteopontin and one corresponded to a novel rat gene of unknown function. As an example only, transfection of rat osteopontin cDNA into the parental Rama 37 cells produced transformants that induced a high frequency of metastasis compared with vector controls confirming the metastatic capability of the osteopontin gene.

These overall results have established a causal relationship between the Met-DNA's and metastasis on the one hand and the over-or underexpression of certain rat genes, at least one of which is novel, that are linked to the metastatic process in this rat system. Controls with DNA's from nonmalignant, nonmetastatic sources as well as the oncogenes Ha-ras-1, Polyoma Large T Antigen and Polyoma Middle T Antigen failed to induce metastasis establishing the specificity of the inductive processes in this system.

At present the most useful indication of whether a breast or other common cancer will metastasise in the future in a patient is whether the primary tumour has already spread to the local lymph nodes. This test only works on a population basis. For example, in breast cancer, there are many examples of patients with no tumour in the lymph nodes at presentation who later die of metastatic disease and of patients with metastatic deposits in the lymph nodes who live a normal life-span. Thus an accurate test of good predictive value for the occurrence of metastases would be important in selecting those patients for vigorous conventional chemotherapeutic treatments without causing the potentially harmful side-effects in those patients who do not need this treatment.

According to a ninth aspect of the present invention there is provided a probe specific to a DNA comprising, consisting of or containing a metastasis inducing DNA or gene or fragment thereof according to the invention.

By specific is meant hybridises to any target DNA under suitable salt and temperature conditions to allow detection of identical or related DNA molecules.

Preferably the probe is provided as part of a kit which may additionally comprise one or more of the following: a colour indicator; an oligonucleotide

primer; materials for gel analysis, and/or materials for DNA transfer or hybridisation.

The Met-DNA sequences may be detected in tumour or biopsy specimens by standard Southern blotting, PCR-based or in-situ techniques to identify those patients at risk from metastatic disease. Physical methods of detection based on imaging techniques may also be possible. Expression of metastasis - inducing genes may be detected by standard mRNA hybridisation PCR amplification or by antibodies specific for the gene-product.

According to a tenth aspect of the present invention there is provided medicaments adapted to target DNA comprising, consisting of or containing a metastasis inducing DNA or gene or fragment thereof of the invention.

In one embodiment such Met-DNA's, metastasis-inducing genes or fragments thereof, could be targeted in the cancer cells to excise or block their function using synthetic oligonucleotides based on a knowledge of the sequence of the Met-DNA's, metastasis-inducing genes or fragments thereof, of the invention.

In another embodiment such Met-DNA's, metastasis-inducing genes or fragments thereof, may be targeted for treatment using standard antibody and antisense mRNA/ribozyme techniques for detection and for destruction, respectively.

Table 1

Donor DNA	Cells injected[a]	No. rats	Tumours	%	Metastasis	%
None	Rama 37	46	22	48%	0	0%
Human metastatic	R37-Ca2-LT1	20	18	90%	6[b]	33%
Human benign	B-T1	18	18	100%	0	0%
Human/rat metastatic tagged	R37-Ca2-HT	37	29	78%	6[b]	21%
Human/rat metastatic	R37-Ca2-H	31	24	77%	4[b]	17%
Human/rat benign tagged	R37-B-HT	39	31	79%	0	0%
PCR fragment F1	R37-F1	30	28	93%	12[b]	43%
PCR fragment F2	R37-F2	40	36	90%	9[b]	25%

Table 2

Transfecting DNA[a]	No. rats	Tumours	%	Metastasis	%
pSV2*neo*	26	13	50%	0	0%
C2-DNA	18	18	100%	6[b]	33%
C5-DNA	25	25	100%	3	12%
C6-DNA	18	18	100%	9[b]	50%
C9-DNA	23	23	100%	4[b]	17%
C12-DNA	13	13	100%	3[b]	23%
C20-DNA	13	13	100%	3[b]	23%


Primer
5'AATCCAAGCTTGCGGCCGATCAGGCCGAATATGCGGCCGCATTAT- 3'
AGGTTCGAACGCCGGCTAGTCCGGCTTATACGCCGGCGTAATATCGA
HindIII
SfiI
NotI
Defective
HindIII

FIG. 1



FIG. 2



FIG. 3



FIG. 4

Pct/GB97/00074

9600470.0

W P Thompson & Co

10/97